Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

Inclusion Criteria

• •Patients with advanced stage (III/IV) or recurrent ovarian cancer who have been treated to complete remission with standard therapies including primary debulking surgery
• •Cancer antigen 125 (CA-125) level within normal limits for the testing laboratory must be documented 90 days prior to enrollment when the assessment of CA-125 is applicable
• •Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy, prior to enrollment
• •Patients must be at least 28 days post systemic steroids prior to enrollment
• •Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status Score of =\< 2
• •Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
• •Estimated life expectancy of more than 6 months
• •White Blood Cell (WBC) \>= 3000/mm\^3
• •Hemoglobin (Hgb) \>= 10 mg/dl
• •Hematocrit (Hct) \>= 28%
• •Serum creatinine =\< 2.0 mg/dl or creatinine clearance \> 60 ml/min
• •Total bilirubin =\< 2.5 mg/dl
• •Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =\< 3 times upper limit of normal (ULN)
• •Blood glucose \< 1.5 ULN